F-group (family)
2003.1.5.47 PRMT5
Ligands and drugs
143
Member domains
98
with ligand contacts (≤ 4 Å)
68.5% of members
59
with DrugDomain annotations
41.3% of members
45
with a DrugBank compound
31.5% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 2003.1.5.47 belongs to X-group 2003 Rossmann-like, which binds 8.9 ligand superclasses per 20 proteins, broader than 78% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB02282 | MTA | 5'-S-methyl-5'-thioadenosine | 20 |
| DB01910 | SFG | Sinefungin | 9 |
| DB00640 | ADN | Adenosine | 5 |
| DB01752 | SAH | S-adenosyl-L-homocysteine | 5 |
| DB00118 | SAM | Ademetionine | 3 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| MTA | 5'-DEOXY-5'-METHYLTHIOADENOSINE | 48 |
| SFG | SINEFUNGIN | 15 |
| CL | CHLORIDE ION | 9 |
| SAM | S-ADENOSYLMETHIONINE | 7 |
| UNL | Unknown ligand | 6 |
| ADN | ADENOSINE | 5 |
| SAH | S-ADENOSYL-L-HOMOCYSTEINE | 5 |
| YFU | 1-ethyl-8-[(2-methoxy-7-azaspiro[3.5]nonan-7-yl)carbonyl]-4-[2-oxidanylidene-2-[(3~{S})-1,2,3,4-tetrahydroisoquinolin-3-yl]ethyl]-2,3-dihydro-1,4-benzodiazepin-5-one | 4 |
| 3XV | N-[(2S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl]-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide | 3 |
| ZR4 | 7-[(5R)-5-C-(4-chloro-3-fluorophenyl)-beta-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine | 3 |
| A1BV0 | N-(6-amino-5-ethylpyridin-3-yl)-2-{(2R,5S)-5-methyl-2-[2-(1-methylpiperidin-4-yl)-1,3-benzothiazol-5-yl]piperidin-1-yl}-2-oxoacetamide | 2 |
| A1BV2 | N-(6-amino-5-methylpyridin-3-yl)-2-{(2R,5S)-5-methyl-2-[2-(1-methylpiperidin-4-yl)-1,3-benzothiazol-5-yl]piperidin-1-yl}-2-oxoacetamide | 2 |
| ZR1 | (1S,2S,3S,5R)-3-{[6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl]oxy}-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol | 2 |
| 0XU | (2S,5S,6E)-2,5-diamino-6-[(3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxydihydrofuran-2(3H)-ylidene]hexanoic acid | 1 |
| 4Z2 | 2-(cyclobutylamino)-N-[(2S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl]pyridine-4-carboxamide | 1 |
| 5QH | ~{N}-[(2~{S})-3-(3,4-dihydro-1~{H}-isoquinolin-2-yl)-2-oxidanyl-propyl]-3-pyridin-2-yl-benzamide | 1 |
| 5QJ | (2~{S})-1-(3,4-dihydro-1~{H}-isoquinolin-2-yl)-3-[[4-(3-methylbenzimidazol-5-yl)pyridin-2-yl]amino]propan-2-ol | 1 |
| 5QK | ~{N}-[(2~{R})-3-(3,4-dihydro-1~{H}-isoquinolin-2-yl)-2-oxidanyl-propyl]-2-quinolin-8-yloxy-ethanamide | 1 |
| 5QL | ~{N}-[(2~{S})-3-(3,4-dihydro-1~{H}-isoquinolin-2-yl)-2-oxidanyl-propyl]-3-(oxan-4-ylamino)benzamide | 1 |
| 81X | 4-(aminomethyl)phthalazin-1(2H)-one | 1 |